Close Menu

Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations

Issue: 
DOI: 
10.7727/wimj.2013.241
Pages: 
650–4

ABSTRACT

Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin’s lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers.  In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.  

Accepted: 
24 Feb, 2014
PDF Attachment: 
e-Published: 29 May, 2014
Top of Page